Comparable patterns of failure between SBRT, lobectomy or pneumonectomy for stage I NSCLC

For patients with medically operable clinical stage I non–small-cell lung cancer (NSCLC), lobectomy or pneumonectomy is the standard approach. For patients with medically inoperable stage I NSCLC, stereotactic body radiotherapy (SBRT) has become a standard of care. Researchers from the Washington University School of Medicine wanted to compare the patterns of failure (primary tumor control, local control, regional control, and distant control) between each method.

A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) , concludes that there are comparable patterns of failure between treatments.

Researchers looked at 454 patients (336 surgery, 118 SBRT) treated at Washington University in St. Louis between January 2004 and January 2008. The results demonstrate that patterns of failure between optimal surgery (lobar resection) and optimally dosed SBRT are similar. However, their results also highlight the difficulties in making such comparisons, given the inherent imbalance in both patient and tumor-related factors. For example, lobar resection patients were younger, healthier, and had superior pulmonary function, while more patients in the SBRT group had smaller tumors.

While researchers were unable to control for factors predictive of overall survival, they were able to match 76 patients in each group based on . Researchers noted, "In a T-stage matched comparison of 152 patients, there was no significant difference in patterns of failure or cancer-specific survival"

They conclude that, "In this retrospective comparison, overall survival was superior for surgery, though cancer-specific survival was similar. Randomized trials are necessary to control for fundamental differences in co-morbidity that impact interpretation of both tumor control and survival."

add to favorites email to friend print save as pdf

Related Stories

ASTRO releases SBRT for lung cancer report

Apr 28, 2010

The American Society for Radiation Oncology (ASTRO) has released its Emerging Technology Committee's report evaluating the use of stereotactic body radiotherapy (SBRT) in lung cancer treatment.

Recommended for you

Cancer: Tumors absorb sugar for mobility

1 hour ago

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness ...

Early hormone therapy may be safe for women's hearts

10 hours ago

(HealthDay)—Healthy women at low risk of cardiovascular disease may be able to take hormone replacement therapy soon after menopause for a short time without harming their hearts, according to a new study.

Low yield for repeat colonoscopy in some patients

11 hours ago

(HealthDay)—Repeat colonoscopies within 10 years are of little benefit to patients who had no polyps found on adequate examination; however, repeat colonoscopies do benefit patients when the baseline examination was compromised, ...

Cell's recycling center implicated in division decisions

13 hours ago

Most cells do not divide unless there is enough oxygen present to support their offspring, but certain cancer cells and other cell types circumvent this rule. Researchers at The Johns Hopkins University have now identified ...

User comments